-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

ASH-FDA Joint Symposium: Novel Approvals in Non-Malignant Hematology

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Clinical Research, Therapies
Monday, December 12, 2022: 4:30 PM-6:00 PM
Great Hall AD (Ernest N. Morial Convention Center)

Tanya Wroblewski, MD

Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD

Carrie Diamond, MD

U.S. Food and Drug Administration, Silver Spring, MD

David J. Kuter, MD, DPhil

Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Tanya Wroblewski, MD

Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD

Josef T. Prchal, MD

Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Tanya Wroblewski, MD

Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD

Gaurav Goyal, MD

Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL